Navigation Links
FDA OKs Avastin for Advanced Breast Cancer
Date:2/22/2008

Drug has significant risks, experts say

FRIDAY, Feb. 22 (HealthDay News) -- The U.S. Food and Drug Administration went against the recommendation of its own advisory panel on Friday and approved the cancer drug Avastin for women with advanced breast cancer.

The agency cleared the drug, made by Genentech and already approved for treating lung and colon cancer, based on findings that it slowed tumor growth, the Associated Press reported.

In a prepared statement issued Friday afternoon, Genentech said the drug won accelerated approval "in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer. The approval is based on a Phase III study, called E2100, that showed that Avastin in combination with paclitaxel chemotherapy resulted in a 52 percent reduction in the risk of disease progression or death compared to those treated with paclitaxel alone and a doubling in progression-free survival."

"There is no cure for metastatic breast cancer, so it is important to control the disease as early and for as long as possible," Dr. Kathy Miller, lead investigator on the E2100 trial, said in the Genentech statement. "Now with Avastin plus paclitaxel, we can increase the time a womans cancer is kept under control, and offer a biologic option to women who previously were limited to chemotherapies alone," added Miller, an associate professor of medical oncology at Indiana University School of Medicine.

Last December, an expert panel of advisers to the FDA voted 5-4 that the drug's ability to slow down the growth of tumors did not outweigh the increased risk of blood clots and other cardiovascular troubles among users. In rare cases, patients taking Avastin with standard chemotherapy have died.

"Everybody wants to offer metastatic breast cancer patients hope, but we shouldn't offer them false hope," panel member Natalie Compagni-Portis, a patient representative with Breast Cancer Action in San Francisco, said during the December meeting, according to the AP. "We have to raise the bar in terms of safety."

"These patients are terminal, and it's our job to make their lives better, not to say that it's OK to have a stroke or that it's manageable," Maha Hussain, an oncologist at the University of Michigan and the advisory panel's chairwoman, said during the meeting. "You didn't show that patients are living better or that they're living longer."

In trial results submitted to the FDA by Genentech before the advisory panel met the use of Avastin (bevacizumab) did boost the progression-free survival of women with advanced breast cancer by an average of 5.5 months, when combined with the chemotherapy drug paclitaxel. Progression-free survival refers to survival without any advancement of the malignancy.

However, the same study of 722 patients showed that patients reaped no gain in terms of their overall survival after taking Avastin.

Avastin is not traditional chemotherapy, but instead is a monoclonal antibody that robs tumors of their blood supply. It has been found to boost the survival of patients with metastatic colorectal cancer and non-small-cell lung cancer when added to chemotherapy and used as a first-line treatment.

According to Bloomberg News, Avastin is currently being tested against 20 cancers in 300 trials. This latest approval is expected to add more than $700 million in annual sales to Genentech's bottom line.

More information

Find out more about breast cancer and its treatment at the American Cancer Society.



SOURCES: Feb. 22, 2008, prepared statement, Genentech Inc., San Francisco; Associated Press; Dec. 5, 2007, FDA Briefing Document, Oncology Drug Advisory Committee Meeting


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
2. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
3. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
4. Taxol with avastin produces noteworthy results
5. FDA Panel Says No to Avastin for Advanced Breast Cancer
6. Perot Systems and Oakwood Healthcare Deliver Advanced Technology & Revenue Cycle Solutions to Physicians
7. American Imaging Management Launches Patient Safety Program to Increase Awareness of Radiation Dose Associated with Advanced Imaging Procedures
8. Combo Treatment Best for Melanoma, Advanced Ovarian Cancer
9. Major study links insurance status to advanced stage in multiple cancers
10. Early warning: PSA testing can predict advanced prostate cancer
11. PSA testing can predict advanced prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA OKs Avastin for Advanced Breast Cancer
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College ... academic programs. , Answering to the increasing demand for curricular specializations, the Certificate ... and environmental and land use law. ,  , “The demand for lawyers with ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
Breaking Medicine Technology: